GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
14 mars 2024 08h45 HE
|
GRI Bio, Inc.
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a...
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
01 févr. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects
31 juil. 2023 07h59 HE
|
Sixty Degrees Pharmaceuticals
Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035.Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’...
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
31 mai 2017 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
16 déc. 2014 08h38 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
10 mars 2014 07h46 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...
P2D Bioscience Announces Enhanced Patent Position for Lead ADHD Drug
26 avr. 2011 10h15 HE
|
P2D Bioscience
CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Apr 26, 2011) - www.p2dinc.com ...